2025-01-17 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis Report

**1. Performance Comparison & Outperformance:**

Intuitive Surgical Inc. (ISRG) is a company that develops and manufactures robotic-assisted surgery systems.  Over the reviewed period, ISRG significantly outperformed the S&P 500 (VOO).  The cumulative return for ISRG is 322.29%, while the S&P 500 returned 116.43%.  The difference in cumulative returns is 205.9 percentage points. This places ISRG at the 99.7th percentile of its historical relative performance against the S&P 500, based on the provided data's min and max range. The provided CAGR (Compound Annual Growth Rate) of 322% over 2015-2025 further emphasizes this substantial outperformance.  Alpha of 206% and Beta of 0 suggest that the stock's returns are largely independent of the market.  However, it's crucial to note that a Beta of 0 is unusual and may warrant further investigation regarding the accuracy or limitations of the beta calculation. A market capitalization of 206 billion is also reported.


**2. Recent Price Movement:**

As of the last market close, ISRG's price was $579.17.  The recent price movements show upward momentum:

* **5-day moving average:** $557.05
* **20-day moving average:** $538.48
* **60-day moving average:** $533.60

The price is above all three moving averages, suggesting a short-term uptrend. The difference between the last market price ($579.17) and the closing price ($579.02) is negligible and doesn't indicate a significant jump or fall.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 68.09.  This indicates the stock is in overbought territory, suggesting a potential pullback may be imminent.

* **PPO (Percentage Price Oscillator):** 0.84. A positive value suggests bullish momentum.

* **Delta_Previous_Relative_Divergence:** +3.4. This indicates a short-term upward trend in relative strength compared to the S&P 500.

* **Expected Return:** 16.7%. This represents the expected excess return compared to the S&P 500 over a long-term (2+ years) investment horizon, assuming current trends continue.  This is a significant potential excess return.

**4. Recent Earnings Analysis:**

The provided earnings data shows consistent growth in both EPS and revenue:

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2024-10-18 | $1.59 | $2.04B       |
| 2024-07-19 | $1.48 | $2.01B       |
| 2024-04-19 | $1.54 | $1.89B       |
| 2023-10-20 | $1.18 | $1.74B       |
| 2024-10-18 | $1.18 | $1.74B       | *(Duplicate Entry - Possible Data Error)*

There's a noticeable increase in both EPS and revenue from Q4 2023 to Q3 2024, suggesting strong financial performance.  The duplicate entry for October 18th, 2024 needs clarification.


**5. Financial Information:**

The financial data shows high profit margins and consistent revenue growth, though ROE (Return on Equity) has fluctuated somewhat:


**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $2.04B | 67.41%       |
| 2024-06-30 | $2.01B | 68.30%       |
| 2024-03-31 | $1.89B | 65.87%       |
| 2023-12-31 | $1.93B | 66.24%       |
| 2023-09-30 | $1.74B | 66.94%       |


**Capital and Profitability:**

| Quarter | Equity     | ROE  |
|---------|------------|------|
| 2024-09-30 | $15.58B    | 3.63% |
| 2024-06-30 | $14.71B    | 3.58% |
| 2024-03-31 | $13.96B    | 3.90% |
| 2023-12-31 | $13.31B    | 4.56% |
| 2023-09-30 | $12.54B    | 3.32% |


The consistently high profit margins indicate strong operational efficiency.  The increase in equity reflects the company's financial health.  The fluctuation in ROE requires further investigation to understand underlying factors.


**7. Overall Analysis:**

ISRG demonstrates exceptional growth and outperformance compared to the S&P 500.  High profit margins and increasing revenue indicate strong financial health.  While the RSI suggests a potential short-term correction, the long-term outlook appears positive, supported by the high expected return.  However, the unusual beta of 0 and some inconsistencies in the data (duplicate earnings entry) warrant further scrutiny.  Investors should conduct thorough due diligence before making investment decisions.  The extremely high CAGR and Alpha numbers deserve careful consideration as they may not be fully representative of longer term and more diverse datasets.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  The information presented is based on the data provided and may not reflect the complete picture.  Independent research and consultation with a financial advisor are recommended before making any investment decisions.
